# US 2014/0193843 A1 · Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193843 A1 - Document ID: US20140193843A1 - Status: Published application - Kind: A1 - Application number: 14/181,056 - Filed: 2014-02-14 - Published: 2014-07-10 - Earliest claimed: 2008-11-28 - Assignees: Institut Pasteur - Inventors: Catherine ROUGEOT; Evelyne Dufour; Sylvie Villard-Saussine; Marie-Noelle Ungeheuer; Pierre Jouannet - Web page: https://patentgrep.com/patent/US20140193843A1 ## CPC - G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds} - C07K 16/26: against hormones {; against hormone releasing or inhibiting factors} - G01N 33/6893: {related to diseases not provided for elsewhere} - G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease} - G01N 2800/28: Neurological disorders - G01N 2800/30: Psychoses; Psychiatry - G01N 2800/344: Disorders of the penis and the scrotum and erectile dysfuncrion - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - G01N 2800/56: Staging of a disease; Further complications associated with the disease - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The present invention relates to the use of Basic Prolin-rich Lacrimal protein (BPLP) gene products, such as Opiorphin, for establishing a prognosis, a diagnosis or the monitoring of a pathological state or of treatment efficacy in a subject and the related method of use. ## Claims ### Claim 1 (canceled) ### Claim 2 A method comprising quantitatively measuring a maturation product of a human BPLP protein in a biological sample obtained from a subject, wherein the biological sample is semen or tears. ### Claim 3 (depends on 2) The method of claim 2, wherein the maturation product is Opiorphin consisting of sequence QRFSR (SEQ ID NO: 3). ### Claim 4 (depends on 2) The method of claim 2, wherein the maturation product is extracted from the sample by acid-methanol extraction. ### Claim 5 (depends on 4) The method of claim 4, wherein the biological sample is semen and the biological sample is acidified with HCl at a final concentration of 0.1 N and treated with EDTA at a final concentration of 1 mM prior to the acid-methanol extraction. ### Claim 6 (depends on 2) The method of claim 2, wherein the quantitative measuring is performed with an immunoassay. ### Claim 7 (depends on 6) The method of claim 6, wherein the immunoassay comprises an anti-QRFSR (SEQ ID NO: 3) antibody. ### Claim 8 (depends on 7) The method of claim 7, wherein the anti-QRFSR (SEQ ID NO: 3) antibody is obtained by: a) administering a peptide of SEQ ID NO: 4, covalently conjugated to an ovalbumin-(CO—NH)— molecule, to a non-human animal; and b) selecting a polyclonal antibody specifically binding to the conjugated peptide of (a). ### Claim 9 (depends on 7) The method of claim 7, wherein the anti-QRFSR (SEQ ID NO: 3) antibody is obtained by: a) administering a peptide of SEQ ID NO: 4, covalently conjugated to an ovalbumin-(CO—NH)— molecule, to a non-human animal; b) removing an immunoglobulin-secreting lymphocyte from the non-human animal; c) fusing the removed lymphocyte with a myeloma cell to obtain at least one immunoglobulin-secreting hybridoma; d) selecting a hybridoma that secretes an antibody specifically binding to the conjugated peptide of (a); and e) isolating the antibody specifically binding to the conjugated peptide of (a). ### Claim 10 (depends on 8) The method of claim 8, wherein the non-human animal is a rabbit. ### Claim 11 (depends on 9) The method of claim 9, wherein the non-human animal is a rabbit. ### Claim 12 (depends on 10) The method of claim 10, comprising: a) coating a micro-titration plate with a peptide of SEQ ID NO: 4 in which a 6-polyethylene or a 12-polyethylene linker has been introduced between the first and second residues; b) adding to the micro-titration plate the sample and the polyclonal antibody that specifically binds to the conjugated peptide; c) adding a labelled anti-rabbit antibody to the micro-titration plate; d) adding a chromogenic substrate suitable for detecting the labelled anti-rabbit antibody to the micro-titration plate; and e) detecting a signal emitted by the chromogenic substrate. ### Claim 13 (depends on 11) The method of claim 11, comprising: a) coating a micro-titration plate with a peptide of SEQ ID NO: 4 in which a 6-polyethylene or a 12-polyethylene linker has been introduced between the first and second residues; b) adding to the micro-titration plate the sample and the polyclonal antibody that specifically binds to the conjugated peptide; c) adding a labelled anti-rabbit antibody to the micro-titration plate; d) adding a chromogenic substrate suitable for detecting the labelled anti-rabbit antibody to the micro-titration plate; and e) detecting a signal emitted by the chromogenic substrate. ### Claim 14 (depends on 2) The method of claim 2, wherein the biological sample is semen. ### Claim 15 (depends on 2) The method of claim 2, wherein the biological sample is tears.